AMENDMENTS TO THE ABSTRACT

Please delete the Abstract of the Invention on page 32 and replace with the following new Abstract:

--The invention encompasses the use of gene therapy for the treatment of different kinds of fibrosis in human beings. Specifically, the invention encompasses the use of therapeutic genes specifically directed to target organs to revert and/or prevent the development of the fibrosis process. The invention further encompasses genes encoding for proteins including human MMP-8 active and latent, MMP-1, MMP-2, MMP-9 and MMP-13; human uPA wild type and/or modified (or its truncated version), the truncated receptor for TGF-β type II and Smad-7, which can be directed by adenovirus and/or other recombinant vectors that cannot transduce (*i.e.*, infect) others organs. The gene therapy of the invention further encompasses treating disorders including renal fibrosis, pulmonary fibrosis, hypertrophic and keloid scars (*i.e.*, skin fibrosis), and other kinds of fibrosis.--